Gero
gero.ai
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Gero applies machine learning to large biomedical and wearable datasets to study the biology of ageing. Founded in 2015 by physicists, it identifies drug targets that affect the rate of biological ageing itself. Its published work on resilience and lifespan has drawn wide scientific attention.
News
AI Discovery Awards 2026
Build and scale faster on the purpose-built AI cloud, engineered from silicon to API.
Read more
Report
Press Release Event Podcast Publication Gero Reaches 34M in Equity Funding to Turn the Physics of Aging Into Medicines June 17, 2026
Gero Reaches 34M in Equity Funding to Turn the Physics of Aging Into Medicines
Read more
Report
Press Release Event News Publication Gero Named World Economic Forum 2026 Technology Pioneer for Advancing the Physics of Aging in Drug Discovery June 10, 2026
Gero Named World Economic Forum 2026 Technology Pioneer for Advancing the Physics of Aging in Drug Discovery
Read more
Report
Why Everything You've Heard About Longevity Is Too Small
My JPM 2026 talk on why the field is asking the wrong questions - and what physics reveals about the real problem
Read more
Report
Pro access
Upgrade to see all 40 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.